Kevin Bitterman - Editas Medicine Independent Director

EDIT Stock  USD 7.42  0.02  0.27%   

Director

Mr. Kevin J. Bitterman, Ph.D., is Independent Director of the company. He has served as a member of our board of directors since June 2014. From November 2013 until June 2014, Dr. Bitterman served as our President. Dr. Bitterman currently serves as a partner at venture firm Polaris Partners, or Polaris, where he was employed since 2004 and where he focuses on investments in life sciences companies. Dr. Bitterman is a cofounder of Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline plc., and was the founding CEO at Visterra Inc. and Morphic Rock, LLC. Dr. Bitterman serves as a director of Genocea Biosciences, Inc., a public biopharmaceutical company, and of Direct Vet Marketing, Inc., Epacing Inc., Kala Pharmaceuticals, Inc., KSQ Therapeutic, LLC, Morphic Rock Therapeutic LLC, Neuronetics, Inc., and TARIS Biomedical, Inc., each a private company since 2014.
Age 40
Tenure 10 years
Professional MarksPh.D
Address 11 Hurley Street, Cambridge, MA, United States, 02141
Phone617 401 9000
Webhttps://www.editasmedicine.com
Bitterman received a Ph.D. in genetics from Harvard Medical School and a B.A. in biological sciences from Rutgers College. We believe that Dr. Bitterman’s extensive experience investing in, guiding, and leading startup and early phase companies, as well as his experience as a director of other companies, qualifies him to serve as a member of our board of directors.

Editas Medicine Management Efficiency

The company has return on total asset (ROA) of (0.2087) % which means that it has lost $0.2087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4317) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.41 in 2024. Return On Assets is likely to drop to -0.32 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.
The company currently holds 36.54 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Editas Medicine has a current ratio of 12.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Editas Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Editas Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Editas Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Editas to invest in growth at high rates of return. When we think about Editas Medicine's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

DIRECTOR Age

Robert HerboldAgilent Technologies
74
Heidi KunzAgilent Technologies
66
Heidi FieldsAgilent Technologies
60
Vickie DriverMediwound
N/A
Aharon YaariMediwound
63
Hans BishopAgilent Technologies
56
Paul ClarkAgilent Technologies
72
Mala AnandAgilent Technologies
53
George ScangosAgilent Technologies
72
Stephen WillsMediwound
58
Dow WilsonAgilent Technologies
61
Tadataka YamadaAgilent Technologies
74
Daniel PodolskyAgilent Technologies
67
Sue RatajAgilent Technologies
63
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people. Editas Medicine (EDIT) is traded on NASDAQ Exchange in USA. It is located in 11 Hurley Street, Cambridge, MA, United States, 02141 and employs 265 people. Editas Medicine is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Editas Medicine Leadership Team

Elected by the shareholders, the Editas Medicine's board of directors comprises two types of representatives: Editas Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Editas. The board's role is to monitor Editas Medicine's management team and ensure that shareholders' interests are well served. Editas Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Editas Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kevin Bitterman, Independent Director
Alexandra Glucksmann, COO
John Mendlein, Independent Director
Boris Nikolic, Independent Director
Vickesh Myer, CTO
Douglas Cole, Independent Director
Andrew Hirsch, Director
Gilmore MD, CEO President
Alexis Borisy, Independent Director
Gerald Cox, Chief Medical Officer
Gilmore ONeill, CEO President
James Mullen, Chairman of the Board
Mark Mullikin, Investor Relations Officer
Michelle Robertson, Principal CFO
Harry III, VP Operations
Eric Ek, Interim CFO, Principal Accounting Officer and Principal Financial Officer
Baisong MD, Senior Officer
Andrew Hack, CFO
Jessica Hopfield, Director
Linda Burkly, Executive Officer
Cynthia Collins, Director
Katrine Bosley, President CEO, Director
Doug Cole, Independent Director
Akshay Vaishnaw, Director
Charles Albright, Chief Scientific Officer
David Scadden, Director
Bruce Eaton, Exec Officer
Cristi Barnett, Corporate Relations
Charlene JD, Executive Counsel
David Liu, CoFounder Member
Mark Shearman, Ex Officer
Feng Zhang, CoFounder Member
Linea Aspesi, Executive Officer
CPA CFA, CFO VP
George Church, CoFounder Member

Editas Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Editas Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Editas Medicine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.

Moving together with Editas Stock

  0.74MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr

Moving against Editas Stock

  0.55CLVRW Clever Leaves HoldingsPairCorr
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Editas Medicine is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Editas Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Editas Medicine Stock. Highlighted below are key reports to facilitate an investment decision about Editas Medicine Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Editas Stock analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.02)
Revenue Per Share
1.028
Quarterly Revenue Growth
8.187
Return On Assets
(0.21)
Return On Equity
(0.43)
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.